Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nabilone

FDA-approved product (capsule, oral), marketed as Cesamet.

Registered studies
35
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Nabilone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Nausea
  • Nausea and vomiting
  • Post operative nausea and vomiting

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiemetics
FDA pharmacologic class
Cannabinoid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

35registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nabilone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nabilone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Nabilone in Cannabis Users With PTSD

    NCT03251326 · start 2015-10

    Registered record
    Registry ID
    NCT03251326
    Conditions
    Cannabis; Post Traumatic Stress Disorder
    Interventions
    Nabilone; Cannabis; Propranolol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2015-10
    Completion
    2019-06
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCannabis; Post Traumatic Stress Disorder
    InterventionNabilone; Cannabis; Propranolol; Placebo
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Safety and Efficacy of Nabilone in Alzheimer's Disease

    NCT02351882 · start 2015-01

    Registered record
    Registry ID
    NCT02351882
    Conditions
    Alzheimer Disease; Agitation; Weight Loss; Pain; Oxidative Stress
    Interventions
    Nabilone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2015-01
    Completion
    2019-03
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Agitation; Weight Loss; Pain +1 more
    InterventionNabilone; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients

    NCT02802540 · start 2014-12

    Registered record
    Registry ID
    NCT02802540
    Conditions
    Non-Small Cell Lung Cancer; Anorexia; Cachexia; Weight Lose
    Interventions
    Nabilone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2014-12
    Completion
    2017-07
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer; Anorexia; Cachexia; Weight Lose
    InterventionNabilone; Placebo
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain

    NCT03210766 · start 2014-09-01

    Registered record
    Registry ID
    NCT03210766
    Conditions
    FBSS
    Interventions
    Nabilone; THC/CBD
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-09-01
    Completion
    2016-01-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFBSS
    InterventionNabilone; THC/CBD
    PhaseNot recorded
    Registry statusCompleted

  • Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet

    NCT02115529 · start 2014-04

    Registered record
    Registry ID
    NCT02115529
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    Nabilone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-04
    Completion
    2015-11
    Enrolment
    331

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    InterventionNabilone; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons

    NCT01222468 · start 2012-06

    Registered record
    Registry ID
    NCT01222468
    Conditions
    Muscle Spasticity as a Result of Spinal Cord Injury
    Interventions
    nabilone 0.5 mg; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-06
    Completion
    2015-02
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMuscle Spasticity as a Result of Spinal Cord Injury
    Interventionnabilone 0.5 mg; placebo
    PhasePhase 2
    Registry statusCompleted

  • The Role of Endocannabinoids in Insulin Production and Action

    NCT01517100 · start 2012-01-05

    Registered record
    Registry ID
    NCT01517100
    Conditions
    Healthy Volunteers
    Interventions
    Nabilone; CP-945,598; hyperglycemic clamp; euglycemic-hyperinsulinemic clamp; Nabilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-01-05
    Completion
    2014-10-06
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionNabilone; CP-945,598; hyperglycemic clamp; euglycemic-hyperinsulinemic clamp +1 more
    PhasePhase 1
    Registry statusCompleted

  • Nabilone for Cannabis Dependence: A Pilot Study

    NCT01347762 · start 2010-06

    Registered record
    Registry ID
    NCT01347762
    Conditions
    Cannabis Dependence; Marijuana Dependence
    Interventions
    Nabilone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2010-06
    Completion
    2017-06-09
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCannabis Dependence; Marijuana Dependence
    InterventionNabilone; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Nabilone & Marijuana Addiction

    NCT01025700 · start 2009-06

    Registered record
    Registry ID
    NCT01025700
    Conditions
    Marijuana Smoking
    Interventions
    Cesemat
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2009-06
    Completion
    2010-10
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMarijuana Smoking
    InterventionCesemat
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Nabilone for the Treatment of Phantom Limb Pain

    NCT00699634 · start 2009-01

    Registered record
    Registry ID
    NCT00699634
    Conditions
    Phantom Limb Pain; Neuropathic Pain
    Interventions
    Nabilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-01
    Completion
    2011-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhantom Limb Pain; Neuropathic Pain
    InterventionNabilone
    PhasePhase 2
    Registry statusCompleted

  • Efficacy Study of Nabilone in the Treatment of Diabetic Peripheral Neuropathic Pain

    NCT01035281 · start 2008-01

    Registered record
    Registry ID
    NCT01035281
    Conditions
    Diabetic Neuropathies
    Interventions
    Nabilone, flexible dosing
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-01
    Completion
    2011-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Neuropathies
    InterventionNabilone, flexible dosing
    PhasePhase 3
    Registry statusUnknown

  • Randomized Double Blind Cross Over Study for Nabilone in Spasticity in Spinal Cord Injury Persons

    NCT00623376 · start 2007-07

    Registered record
    Registry ID
    NCT00623376
    Conditions
    Spasticity in Spinal Cord Injured Persons
    Interventions
    nabilone then placebo; placebo then nabilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-07
    Completion
    2007-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpasticity in Spinal Cord Injured Persons
    Interventionnabilone then placebo; placebo then nabilone
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis

    NCT00480181 · start 2007-06

    Registered record
    Registry ID
    NCT00480181
    Conditions
    Neuropathic Pain; Multiple Sclerosis
    Interventions
    nabilone; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-06
    Completion
    2012-07
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuropathic Pain; Multiple Sclerosis
    Interventionnabilone; placebo
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy

    NCT00380965 · start 2006-10

    Registered record
    Registry ID
    NCT00380965
    Conditions
    Peripheral Neuropathy; Antineoplastic Combined Chemotherapy Protocols
    Interventions
    Cesamet™ (nabilone)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-10
    Completion
    2007-10
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Neuropathy; Antineoplastic Combined Chemotherapy Protocols
    InterventionCesamet™ (nabilone)
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy

    NCT00380913 · start 2006-09

    Registered record
    Registry ID
    NCT00380913
    Conditions
    Diabetic Neuropathies
    Interventions
    Cesamet™ (nabilone)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-09
    Completion
    2007-10
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Neuropathies
    InterventionCesamet™ (nabilone)
    PhasePhase 4
    Registry statusCompleted